Hypolipidaemic Agents in the Treatment of Xanthomata

  • N. E. Miller
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 87 / 2)


Animal studies (Kodama et al. 1981) and the resolution of xanthomata in many hyperlipidaemic patients after plasma lipid reduction (Hessel et al. 1976) have confirmed that the association between plasma lipids and xanthoma formation is causal. Accordingly, the treatment of hyperlipidaemia is an important component of the management of xanthomatous patients. Not all types of hyperlipidaemia produce xanthomata, and the nature of the lesions varies according to the lipoprotein class (Hessel et al. 1976). The lipoprotein patterns found in association with different forms of xanthomata are presented in Table 1 and the causes in Table 2 (Lewis 1976).


Glycogen Storage Disease Familial Hypercholesterolaemia Familial Combine Hyperlipidaemia Hyperlipidaemic Patient Plasma Lipid Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barber MJ, Gilmour FR, Mueller TM, Zipes DP (1981) Electrophysiological effects of probucol on monkey ventricle. Circulation 64:IV–123Google Scholar
  2. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T (1970) Classification of hyperlipidaemis and hyperlipoproteinaemias. Bull WHO 43:891–915PubMedGoogle Scholar
  3. Grundy SM, Mok HYI, Zech L, Berman M (1981) Influence of nicotinic acid on the metabolism of cholesterol and triglycerides in man. J Lipid Res 22:24–36PubMedGoogle Scholar
  4. Hessel LW, Vermeer BJ, Polano MK, de Jonge H, de Pagter HAT, van Get CM (1976) Primary hyperlipoproteinaemia in xanthomatosis. Clin Chim Acta 69:405–416PubMedCrossRefGoogle Scholar
  5. Kane JP, Malloy MJ, Tun P, Phillips NR, Freedman DD, Williams ML, Rowe JS, Havel RJ (1981) Normalization of low density lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 304:251–258PubMedCrossRefGoogle Scholar
  6. Kodama H, Nagao Y, Arakawa K, Tada J, Nohara N (1981) Cholesterol synthesis and esterification in experimental xanthoma tissues. J Lipid Res 22:1033–1041PubMedGoogle Scholar
  7. Lewis B (1976) The hyperlipidaemias. Blackwell, OxfordGoogle Scholar
  8. Miller NE, Clifton-Bligh P, Nestel PJ, Whyte HM (1973) Controlled clinical trial of a new bile acid-sequestering resin colestipol, in the treatment of hypercholesterolaemia. Med J Aust 1:1223–1227PubMedGoogle Scholar
  9. Miller NE, Mjos OD, Oliver MF (1976) Effects of p-chlorophenoxyisobutyrate on free fatty acid mobilization from canine subcutaneous adipose tissue in situ. Clin Sci 51:107–110Google Scholar
  10. Nestel PJ, Billington T (1981) Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 38:203–209PubMedCrossRefGoogle Scholar
  11. Noseda G, Lewis B, Paoletti R (1980) Diet and drugs in atherosclerosis. Raven, New YorkGoogle Scholar
  12. Rose HG, Haft GK, Juliano J (1976) Clofibrate-induced low density lipoprotein elevation. Atherosclerosis 23:413–427PubMedCrossRefGoogle Scholar
  13. Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG (1980) Cholestyramine promotes receptor-mediated low density lipoprotein catabolism. N Engl J Med 302:1219–1222PubMedCrossRefGoogle Scholar
  14. WHO (1980) WHO cooperative trial on primary prevention of ischaemic heart disease using Clofibrate to lower serum cholesterol: mortality follow-up. Lancet 2:379–385Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • N. E. Miller

There are no affiliations available

Personalised recommendations